Boston, MA - June 22, 1999 -- Opening a new avenue for understanding and perhaps eventually treating Alzheimer's disease, researchers from Boston and New York have identified an enzyme that appears to restore the function of a key player in Alzheimer's disease. The enzyme, known as Pin1, is depleted in brains of people with Alzheimer's disease, according to a paper in the June 24 issue of the weekly journal Nature.
"This is the first study to show a potential role for Pin1 in Alzheimer's disease," says cell biologist and senior author Kun Ping Lu MD PhD, an associate physician at Beth Israel Deaconess Medical Center in Boston and an assistant professor of medicine at Harvard Medical School.
Affecting an estimated 4 million people nationwide, Alzheimer's disease is the most common cause of dementia in older people. The disease disrupts memory, thought and language in the brain by damaging synapses and killing nerve cells. Abnormal clumps called plaques and tangled bundles of fibers are the two major hallmarks of Alzheimer's. Scientists do not know exactly how these changes relate to the loss of nerve cells and brain atrophy. Plaques can occur in the brain without much change in brain function, but tangles appear to be more directly associated with dementia. Pin1 may play a role in the formation -- or prevention -- of tangles.
The neurofibrillary tangles in Alzheimer's occur inside individual nerve cells. The tangles are largely composed of the long protein tau. Normally, tau's job is assembling and maintaining the microtubules that stretch from one end of the nerve cell to the other. Microtubules keep the long nerve axons healthy from the muscle to the brain by transporting cell nourishment and structural components.
Tau can be derailed from a microtubule when too many phosphates leap on board the tau and change tau's shape. The distorted tau cannot maintain the microtubules. The microtubules fall apart, infering with a nerve's crucial function of transmitting signals. Clogging up the works even further, the distorted tau proteins then tangle together.
"There's a lot of evidence over the last two years that shape changes in tau can be lethal to nerve cells and are important in neuronal degeneration in Alzheimer's," says co-author Peter Davies PhD, Resnick Professor of Alzheimer's Disease Research at Albert Einstein College of Medicine in New York. "Pin1 is the first molecule known to change the shape of tau."
According to the new study, Pin1 may restore the function of tau. In a test tube, Lu and his colleagues in Boston added Pin1 to a solution containing both the building blocks of the microtubules and the tau protein misshapen by its attached phosphates. Within 10 minutes, Pin1 had rehabilitated the tau proteins so that the tau, in turn, could assemble long thread-like microtubules.
Unfortunately, nerve cells seem to have a limited capacity to produce enough Pin1 to keep up with phosphate additions to the tau protein. In the brains of patients with Alzheimer's disease, Pin1 is apparently depleted by working overtime to keep fixing tau. For this study, the researchers compared tissue samples from brains of people who had died from Alzheimer's disease to those who had died from other causes. Using different methods, both researchers found Pin1 available and ready for action in normal nerve cells. But in nerve cells of Alzheimer's, most of the available Pin1 was depleted from its usual reservoirs in cells and instead bound up in the tangles with the tau-phosphate molecules.
Ultimately, the researchers have yet to determine whether Pin1, or lack of available Pin1, leads to tangle formation. Depletion of Pin1 itself may be yet another mechanism leading to nerve death in Alzheimer's, where the Pin1 is tied up in the tangles. In other cell types, earlier studies by Lu found Pin1 depletion alone was enough to kill the cells.
Many drug companies are experimenting with substances that may block phosphates from attaching to tau, but this study offers an alternative way to achieve the same function, says Michel Goedert of the MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, who wrote an accompanying commentary for Nature. "The most important observation is the experiment that shows that when Pin1 is added to phosphorylated tau in the test tube, tau is able to fulfill its normal function," he says. However, Goedert cautions that scientists are a long way from showing the therapeutic benefits.
In the last four years, Lu discovered Pin1 and has published a series of studies showing Pin1's important role in normal cell division. Pin1 apparently helps control the timing of cell division by acting on about 50 different proteins that temporarily don extra phosphates for the occasion.
Meanwhile, Davies had been focusing on tau's role in Alzheimer's disease. In one observation, Davies and others noticed that some features of Alzheimer's disease suggested that the nerve cells were trying to divide, which may set up a lethal process of cell death for neurons.
Other authors of the Nature paper included Pei-Jung Lu, Gerburg Wulf and Xiao Zhen Zhou, all postdoctoral fellows of the Cancer Biology Program of Beth Israel Deaconess Medical Center and Harvard Medical School. The research was funded by the National Institutes of Health, Pew Charitable Trusts, Leukemia Society of America, and Department of Energy Breast Cancer Program.
Editors, please note: A graphic will be available on the Web at http://www.hms.harvard.edu/news/images/pin.html on Tuesday, June 22 after 12:00 pm EDT.
The above post is reprinted from materials provided by Harvard Medical School. Note: Materials may be edited for content and length.
Cite This Page: